| 2026-09-03 | Trial | New trial registered: Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer | Trial register ClinicalTrials.gov |
| 2026-09-02 | Results | Results posted: Contributions to Hypertension With Androgen Deprivation Therapy | Trial register ClinicalTrials.gov |
| 2026-08-31 | Results | Results posted: Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) | Trial register ClinicalTrials.gov |
| 2026-08-24 | Federal Register | Federal Register notice: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2026-08-20 | Trial | New trial registered: QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy | Trial register ClinicalTrials.gov |
| 2026-08-06 | Trial | New trial registered: A Phase Ia Trial Comparing the Pharmacokinetics/Pharmacodynamics, Safety, and Preliminary Efficacy of HHK001 and Enantone in Patients With Endometri | Trial register ClinicalTrials.gov |
| 2026-08-03 | Trial | New trial registered: Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis | Trial register ClinicalTrials.gov |
| 2026-07-25 | Trial | New trial registered: Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer | Trial register ClinicalTrials.gov |
| 2026-07-11 | Trial | New trial registered: Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer | Trial register ClinicalTrials.gov |
| 2026-07-07 | Trial | New trial registered: Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer. | Trial register ClinicalTrials.gov |
| 2026-07-06 | Trial | New trial registered: A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty | Trial register ClinicalTrials.gov |
| 2026-07-02 | Results | Results posted: Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients Wi | Trial register ClinicalTrials.gov |
| 2026-06-16 | Trial | New trial registered: Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial | Trial register ClinicalTrials.gov |
| 2026-06-15 | Results | Results posted: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate | Trial register ClinicalTrials.gov |
| 2026-05-28 | Label | FDA label revised: leuprolide acetate (ANDA215336) | Regulator FDA drug label register |
| 2026-05-27 | Results | Results posted: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors | Trial register ClinicalTrials.gov |
| 2026-05-25 | Label | FDA label revised: LEUPROLIDE ACETATE (ANDA215826) | Regulator FDA drug label register |
| 2026-05-19 | Label | FDA label revised: Leuprolide Acetate (ANDA074728) | Regulator FDA drug label register |
| 2026-05-14 | Trial | New trial registered: Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients. | Trial register ClinicalTrials.gov |
| 2026-05-13 | Trial | New trial registered: BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypo | Trial register ClinicalTrials.gov |
| 2026-05-08 | Label | FDA label revised: LEUPROLIDE ACETATE (ANDA212963) | Regulator FDA drug label register |
| 2026-04-30 | Label | FDA label revised: Vabrinty (NDA021379) | Regulator FDA drug label register |
| 2026-04-30 | Label | FDA label revised: Eligard (NDA021379) | Regulator FDA drug label register |
| 2026-04-24 | Label | FDA label revised: leuprolide acetate (ANDA078885) | Regulator FDA drug label register |
| 2026-04-23 | Label | FDA label revised: Leuprolide Acetate (ANDA075471) | Regulator FDA drug label register |
| 2026-04-21 | Trial | New trial registered: A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer | Trial register ClinicalTrials.gov |
| 2026-04-13 | Results | Results posted: AASUR in High Risk Prostate Cancer | Trial register ClinicalTrials.gov |
| 2026-04-09 | Results | Results posted: Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | Trial register ClinicalTrials.gov |
| 2026-04-03 | Results | Results posted: Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW | Trial register ClinicalTrials.gov |
| 2026-03-29 | Label | FDA label revised: leuprolide acetate (ANDA217957) | Regulator FDA drug label register |
| 2026-03-15 | Label | FDA label revised: Lupron Depot (NDA020517) | Regulator FDA drug label register |
| 2026-03-12 | Results | Results posted: Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients | Trial register ClinicalTrials.gov |
| 2026-03-06 | Trial | New trial registered: Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT | Trial register ClinicalTrials.gov |
| 2026-02-24 | Trial | New trial registered: Rezvilutamide for High-Risk Prostate Cancer After Surgery | Trial register ClinicalTrials.gov |
| 2026-02-18 | Label | FDA label revised: CAMCEVI (NDA211488) | Regulator FDA drug label register |
| 2026-02-13 | Results | Results posted: Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer | Trial register ClinicalTrials.gov |
| 2026-02-09 | Label | FDA label revised: LEUPROLIDE ACETATE (ANDA215826) | Regulator FDA drug label register |
| 2026-01-29 | Results | Results posted: Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | Trial register ClinicalTrials.gov |
| 2026-01-28 | Trial | New trial registered: Radiotherapy After Prostatectomy for Node Positive Prostate Cancer | Trial register ClinicalTrials.gov |
| 2026-01-16 | Label | FDA label revised: leuprolide acetate (ANDA217957) | Regulator FDA drug label register |
| 2026-01-13 | Results | Results posted: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty | Trial register ClinicalTrials.gov |
| 2025-12-28 | Trial | New trial registered: Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer | Trial register ClinicalTrials.gov |
| 2025-12-28 | Trial | New trial registered: Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Trial register ClinicalTrials.gov |
| 2025-12-18 | Trial | New trial registered: Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatmen | Trial register ClinicalTrials.gov |
| 2025-12-16 | Trial | New trial registered: Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER) | Trial register ClinicalTrials.gov |
| 2025-12-05 | Results | Results posted: The Role of Hormones in Postpartum Mood Disorders | Trial register ClinicalTrials.gov |
| 2025-12-05 | Results | Results posted: Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT | Trial register ClinicalTrials.gov |
| 2025-11-21 | Label | FDA label revised: Leuprolide Acetate (ANDA213829) | Regulator FDA drug label register |
| 2025-11-16 | Trial | New trial registered: CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer | Trial register ClinicalTrials.gov |
| 2025-11-14 | Label | FDA label revised: Lupron Depot-PED (NDA020263) | Regulator FDA drug label register |
| 2025-09-25 | Label | FDA label revised: Fensolvi (NDA213150) | Regulator FDA drug label register |
| 2025-09-22 | Results | Results posted: RElugolix VErsus LeUprolide Cardiac Trial | Trial register ClinicalTrials.gov |
| 2025-09-18 | Label | FDA label revised: Lupron Depot (NDA020011) | Regulator FDA drug label register |
| 2025-09-18 | Trial | New trial registered: Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study | Trial register ClinicalTrials.gov |
| 2025-09-10 | Label | FDA label revised: Lupron Depot (NDA020708) | Regulator FDA drug label register |
| 2025-09-05 | Trial | New trial registered: Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial | Trial register ClinicalTrials.gov |
| 2025-08-29 | Trial | New trial registered: Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway | Trial register ClinicalTrials.gov |
| 2025-08-20 | Trial | New trial registered: Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATO | Trial register ClinicalTrials.gov |
| 2025-08-19 | Trial | New trial registered: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response | Trial register ClinicalTrials.gov |
| 2025-08-19 | Trial | New trial registered: A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH | Trial register ClinicalTrials.gov |
| 2025-08-14 | Trial | New trial registered: Norethindrone Impact on Receptiva Outcomes | Trial register ClinicalTrials.gov |
| 2025-08-01 | Results | Results posted: Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer | Trial register ClinicalTrials.gov |
| 2025-08-01 | Trial | New trial registered: Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer | Trial register ClinicalTrials.gov |
| 2025-06-26 | Results | Results posted: DeADT - Living Well With Prostate Cancer | Trial register ClinicalTrials.gov |
| 2025-06-24 | Label | FDA label revised: Leuprolide Acetate (ANDA213829) | Regulator FDA drug label register |
| 2025-06-12 | Results | Results posted: Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia | Trial register ClinicalTrials.gov |
| 2025-06-10 | Trial | New trial registered: Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer | Trial register ClinicalTrials.gov |
| 2025-06-03 | Label | FDA label revised: LUTRATE DEPOT (NDA205054) | Regulator FDA drug label register |
| 2025-06-03 | Trial | New trial registered: A Clinical Study of KLH-2109 in Patients With Endometriosis | Trial register ClinicalTrials.gov |
| 2025-05-22 | Trial | New trial registered: The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administere | Trial register ClinicalTrials.gov |
| 2025-04-15 | Trial | New trial registered: Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty | Trial register ClinicalTrials.gov |
| 2025-04-03 | Trial | New trial registered: The COSMYC Trial (COmbined Suppression of MYC) | Trial register ClinicalTrials.gov |
| 2025-02-23 | Trial | New trial registered: Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+ | Trial register ClinicalTrials.gov |
| 2025-02-11 | Trial | New trial registered: Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months. | Trial register ClinicalTrials.gov |
| 2025-01-19 | Trial | New trial registered: Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients | Trial register ClinicalTrials.gov |
| 2024-12-31 | Results | Results posted: Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea | Trial register ClinicalTrials.gov |
| 2024-12-11 | Trial | New trial registered: Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer | Trial register ClinicalTrials.gov |
| 2024-11-26 | Results | Results posted: Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts | Trial register ClinicalTrials.gov |
| 2024-10-21 | Trial | New trial registered: REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | Trial register ClinicalTrials.gov |
| 2024-10-16 | Results | Results posted: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery | Trial register ClinicalTrials.gov |
| 2024-10-16 | Trial | New trial registered: Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Horm | Trial register ClinicalTrials.gov |
| 2024-10-08 | Results | Results posted: Menopausal Sleep Fragmentation and Body Fat Gain | Trial register ClinicalTrials.gov |
| 2024-09-12 | Trial | New trial registered: COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | Trial register ClinicalTrials.gov |
| 2024-08-27 | Label | FDA label revised: LEUPROLIDE ACETATE DEPOT (NDA205054) | Regulator FDA drug label register |
| 2024-07-31 | Results | Results posted: A Study of PF-06873600 in People With Cancer | Trial register ClinicalTrials.gov |
| 2024-07-06 | Trial | New trial registered: A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer | Trial register ClinicalTrials.gov |
| 2024-06-13 | Results | Results posted: Brown Adipose Tissue Activity in Pre- and Postmenopausal Women | Trial register ClinicalTrials.gov |
| 2024-06-13 | Trial | New trial registered: Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer | Trial register ClinicalTrials.gov |
| 2024-06-10 | Label | FDA label revised: LEUPROLIDE ACETATE (ANDA217437) | Regulator FDA drug label register |
| 2024-06-07 | Trial | New trial registered: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. | Trial register ClinicalTrials.gov |
| 2024-05-30 | Trial | New trial registered: Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer | Trial register ClinicalTrials.gov |
| 2024-05-03 | Trial | New trial registered: ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer | Trial register ClinicalTrials.gov |
| 2024-04-30 | Results | Results posted: A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment | Trial register ClinicalTrials.gov |
| 2024-04-29 | Trial | New trial registered: A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer | Trial register ClinicalTrials.gov |
| 2024-04-23 | Federal Register | Federal Register notice: PAI Holdings, LLC DBA Pharmaceutical Associates, Inc., et al.; Withdrawal of Approval of 23 New Drug Applications | Regulator Federal Register |
| 2024-04-23 | Trial | New trial registered: Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiat | Trial register ClinicalTrials.gov |
| 2024-04-04 | Trial | New trial registered: Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma | Trial register ClinicalTrials.gov |
| 2024-03-27 | Results | Results posted: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, | Trial register ClinicalTrials.gov |
| 2024-03-26 | Trial | New trial registered: Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | Trial register ClinicalTrials.gov |
| 2024-03-25 | Results | Results posted: Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | Trial register ClinicalTrials.gov |